Molecular mechanism of Tian-Wang-Bu-Xin-Dan in the treatment of Alzheimer’s disease: a network pharmacology and molecular docking study
Open Access
- 30 June 2026
- journal article
- Published by University of Medicine and Pharmacy at Ho Chi Minh City in MedPharmRes
- Vol. 10 (2) , 187-201
Abstract
Alzheimer’s disease (AD) is increasing in prevalence among aging populations and presents challenges in finding effective treatments. Tian-Wang-Bu-Xin-Dan (TWBXD) is a classical remedy used to treat anxiety, insomnia, dementia, and memory disorders, with neuroprotective, vasorelaxant, hypotensive, and anti-Alzheimer’s effects reported in experimental studies. This study aimed to elucidate TWBXD mechanisms in AD using network pharmacology. Methods: Targets of TWBXD and AD were retrieved from multiple databases. Pathway enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) tool. A protein-protein interaction network was established using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and topological analysis identified core targets. Molecular docking was used to examine the binding affinity between core targets and active compounds. The TWBXD-AD network comprised 174 bioactive compounds and 92 overlapping targets. Enrichment analysis revealed these targets were involved in AD regulation through apoptosis (neurotrophins, PI3K-Akt, and MAPK signaling pathways), inflammation (IL-17, tumor necrosis factor [TNF], and C-type lectin receptor signaling pathways), and neurotransmission (serotonergic synapse and calcium signaling pathways). The most significant core targets identified were INS, AKT1, IL6, IL1B, TNF, BCL2, CASP3, and BDNF, indicating TWBXD primarily targets inflammation, apoptosis, neurotrophic factors, and neuronal growth. Molecular docking yielded favorable predicted docking scores for multiple compound–target pairs. Tanshinone IIA showed relatively low predicted docking scores with several core targets, suggesting potential binding propensity in silico. Active compounds and targets in TWBXD may modulate AD-related pathways associated with apoptosis, inflammation, and neurotransmission. These predictions provide valuable data for further comprehensive studies on the effects, mechanisms, and safety of TWBXD in experimental and clinical settings.Keywords
This publication has 48 references indexed in Scilit:
- In silico methods and tools for drug discoveryComputers in Biology and Medicine, 2021
- IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s diseaseCell Reports, 2021
- Neuroinflammation in Alzheimer's disease and beneficial action of luteolinBioFactors, 2021
- Alzheimer's disease: Recent treatment strategiesEuropean Journal of Pharmacology, 2020
- Alzheimer Disease: An Update on Pathobiology and Treatment StrategiesCell, 2019
- Calcium signaling and molecular mechanisms underlying neurodegenerative diseasesCell Calcium, 2018
- Luteolin as a potential preventive and therapeutic candidate for Alzheimer's diseaseExperimental Gerontology, 2017
- Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer’s diseaseNeurological Sciences, 2015
- Pathological roles of MAPK signaling pathways in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009